Addition of palbociclib improves progression-free survival in HR-positive, HER2-positive metastatic breast cancer

For patients with hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer, the addition of palbociclib to maintenance anti-HER2 and endocrine therapies leads to improved progression-free…

Continue Reading

News Source: medicalxpress.com